COMMUNIQUÉS West-GlobeNewswire

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
01/03/2018
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis' leadership in biomedical research [...]
Biocartis Group NV: BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK
01/03/2018
PRESS RELEASE: REGULATED INFORMATION Thursday, 1 March 2018, 07:02 CET BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK Mechelen, Belgium , 1 March 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an [...]
Biocartis Group NV: Biocartis Establishes R&D Center in the US
01/03/2018
PRESS RELEASE : 1 March 2018, 07:01 CET Biocartis Establishes R&D Center in the US Biocartis team strengthened with joining of Janssen Diagnostic's Idylla(TM) assay development team Mechelen, Belgium, 1 March 2018 [...]
argenx reports fourth quarter business update and full year 2017 financial results
01/03/2018
Management to host conference call today at 3 pm CET / 9 am EST March 1, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep [...]
Biocartis Group NV: European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects
01/03/2018
PRESS RELEASE : REGULATED INFORMATION - INSIDE INFORMATION 1 March 2018, 07:00 CET European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects Mechelen, Belgium, 1 March [...]
Targovax ASA: Issuance of restricted stock unites (RSUs) to the chairman of the board of directors
01/03/2018
Reference is made to the extraordinary general meeting of Targovax ASA (the "Company") on 30 November 2017, where Patrick Vink was elected as chairman of the Company's board of directors and the Company was authorized [...]
Essilor News Release: Solid 2017 earnings Strong fourth quarter
01/03/2018
Solid 2017 earnings Strong fourth quarter PDF Version of the news release Revenue: Up 6.7% at constant exchange rates, up 3.1% like-for-like Robust growth in the United States and e-commerce activities Adjusted [...]
Essilor - Communiqué : Des résultats 2017 solides, un très bon 4ème trimestre
01/03/2018
Des résultats 2017 solides Un très bon 4 ème trimestre Version PDF du communiqué Chiffre d'affaires : + 6,7 % hors change et + 3,1 % en base homogène Dynamisme des Etats-Unis et des activités e-commerce Contribution de [...]
News Release: Essilor to allocate exceptional French tax refund to the Group's initiatives to eradicate poor vision
01/03/2018
Essilor to allocate exceptional French tax refund to the Group's initiatives to eradicate poor vision PDF Version of the news release (Charenton-le-Pont - France, March 1 2018) - Essilor today announces that it will [...]
Communiqué : Essilor reverse la totalité du remboursement exceptionnel d'impôt à son combat contre le mal voir
01/03/2018
Essilor reverse la totalité du remboursement exceptionnel d'impôt à son combat contre le mal voir Version PDF du communiqué (Charenton-le-Pont - France, 1 er mars 2018) - Le Groupe Essilor annonce aujourd'hui qu'il [...]
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
01/03/2018
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]
REVA to Hold Fourth Quarter and Full Year 2017 Financial Results Call
01/03/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) has scheduled a conference call to review its fourth quarter and full year 2017 financial results and provide a [...]
Agility Health Closes Proposed Transaction with Alliance
01/03/2018
GRAND RAPIDS, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Agility Health, Inc. (TSXV:AHI) (“Agility Health” or the “Company”) announced today that it closed its previously announced transaction with Alliance Physical [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/03/2018
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to [...]
Extendicare Announces 2017 Year End Results
28/02/2018
MARKHAM, Ontario, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) today reported results for the fourth quarter and year ended December 31, 2017. Results are presented in [...]
Galectin Therapeutics to Present at 30th Annual ROTH Conference
28/02/2018
NORCROSS, Ga., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s [...]
Retrophin to Present at the Barclays Global Healthcare Conference
28/02/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX ) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday [...]
Intellia Therapeutics to Present at March Healthcare Investor Conferences
28/02/2018
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will [...]
Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results
28/02/2018
GAAP Net Loss cut by 34% from $33.2 in 2016 to $22.0 million in 2017 Adjusted EBITDA loss reduced by 61% from $22.8 million in 2016 to $8.8 million 2017 Filed for Type II variation for uveitis in Europe for ILUVIEN in [...]

Pages